Yazar "Ayas, Selahattin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Cerebrospinal Fluid and Serum Autoantıbodıes in Drug-Resistant Temporal Lobe Epilepsıes: Case Series
    (2023) Kabay, Sibel Canbaz; Tüzün, Erdem; Akdağ, Gönül; Çetiner, Mustafa; Ayas, Selahattin; Karaman, Handan Işın Özışık; Arıkan, Fatma Akkoyun
    We aimed to investigate the presence of neuronal antibodies in serum and cerebrospinal fluid(CSF) analysis of patients with drug resistant temporal lobe epilepsy. We evaluated 8 patients who accepted lumbar puncture with a diagnosis of drug resistant temporal lobe epilepsy. Neuronal autoantibodies were found to be negative in both serum and CSF in all patients. We investigated neuronal antibodies and clinical features in cases who were followed up for drug-resistant temporal lobe epilepsy and suspected of autoimmune epilepsy. Although neuronal antibodies were not detected in CSF and serum examinations, this may be related to the early age of onset in our study group. Autoimmune epilepsy should be considered among the differantial diagnosis with a subacute clinic, unusually high seizure frequency, variety and variability of seizures, resistance to antiseizure medications(ASMs), presence of an autoimmune disease in the person or his/her family, history of cancer or viral prodroma, demonstration of CNS inflammation and detection of neural antibodies.
  • [ X ]
    Öğe
    Long Term Sustained Therapeutic Effects of Percutaneous Posterior Tibial Nerve Stimulation Treatment of Neurogenic Overactive Bladder in Multiple Sclerosis Patients: 12-Months Results
    (Wiley, 2017) Kabay, Sibel Canbaz; Kabay, Sahin; Mestan, Emine; Cetiner, Mustafa; Ayas, Selahattin; Sevim, Mehmet; Ozden, Hilmi
    Aims: The aim of this study is to determine the sustained therapeutic efficacy and treatment intervals for PTNS in NOAB with MS, offering periodic additional treatments during 1 year in patients who completed an initial course of 12 consecutive weekly sessions. Methods: A total of 34 patients enrolled to the PTNS treatment and 21 patients completed the 1 year PTNS treatment with a tapering protocol of 6, 9, and 12 months of therapy, respectively. After 12 weeks of therapy, PTNS was applied at 14 day intervals for 3 months, 21 day intervals for 3 months, and 28 day intervals for 3 months. The patients completed a 3-day voiding diary at 3rd, 6th, 9th, and 12th month. The patients requested to complete validated questionnaires (ICIQ-SF, OAB-V8, OAB-q SF) were carried out within 3-month intervals thereafter during their enrolment in the study. Results: A total of 21 patients were enrolled in the study. Of these 5 (23.8%) were men and 16 (76.2%) women. The improvements for all voiding diary parameters were significant in the 6th, 9th, and 12th months when compared with baseline. Mean values between baseline and 12 month parameters suggested that daytime frequency decreased by 5.4 voids daily, urge incontinence decreased by 3.4 episodes daily, urgency episodes decreased by 7.4 episodes daily, nocturia decreased by 2.6 voids, and voided volume improved by a mean of 72.1 cc. Conclusion: These results have demonstrated NOAB symptom improvement in MS patients can be achieved with 12 weekly PTNS treatments which show excellent durability over 12 months. (C) 2015 Wiley Periodicals, Inc.
  • [ X ]
    Öğe
    The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson's Disease
    (Elsevier Science Inc, 2016) Kabay, Sahin; Kabay, Sibel Canbaz; Cetiner, Mustafa; Mestan, Emine; Sevim, Mehmet; Ayas, Selahattin; Ozden, Hilmi
    OBJECTIVE To investigate the effect of percutaneous posterior tibial nerve stimulation (PTNS) treatment after 12 weeks on urodynamic and clinical findings in patients with Parkinson's disease (PD) with neurogenic detrusor overactivity. METHODS A total of 47 patients with PD with neurogenic detrusor overactivity were enrolled in the study. Urodynamic studies before and after 12-week PTNS treatment were performed. International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), Overactive Bladder Questionnaire (OAB-V8), and Overactive Bladder Questionnaire Short Form (OAB-q SF) have been assessed before and after PTNS treatment. RESULTS The mean first involuntary detrusor contraction volume (1st IDCV) on standard cystometry was 133.2 +/- 48.1 (24-265) mL, whereas it was 237.3 +/- 43.1 (145-390) mL after PTNS. The mean maximum cystometric capacity (MCC) on standard cystometry was 202.2 +/- 36.5 (115-320) mL, whereas it was 292.1 +/- 50.6 (195-395) mL after stimulation. The improvements in the first involuntary detrusor contraction volume and maximum cystometric capacity were statistically significant after stimulation. The mean Pdetmax at first involuntary detrusor contraction, maximal detrusor pressure at maximum cystometric capacity, PdetQmax, Qmax, and post-void residual volume were statistically significant after 12-week stimulation. Mean parametric improvements at 12-week PTNS treatment from baseline included daytime frequency decreased by 5.6 voids daily, urge incontinence decreased by 3.1 episodes daily, urgency episodes decreased by 6.3 episodes daily, nocturia decreased by 2.7 voids, and voided volume improved by a mean of 92.6 mL. The change from baseline on the ICIQ-SF, OABv8, and OAB-q at 12-week PTNS treatment demonstrated statistically significant improvements. CONCLUSION These results have demonstrated that PTNS improves the lower urinary tract symptoms and urodynamic parameters in patients with PD. (C) 2015 Elsevier Inc.